1 / 25

AIDP/CIDP Anal Pap Smear

AIDP/CIDP Anal Pap Smear. Jeffrey A. Beal, M.D. Faculty, Florida/Caribbean AIDS Education Training Center . III.35 AIDP/CIDP. Discuss the clinical presentation, differential diagnosis, and management of acute and chronic inflammatory demyelinating polyneuropathy in HIV+ patients .

betty_james
Download Presentation

AIDP/CIDP Anal Pap Smear

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. AIDP/CIDPAnal Pap Smear Jeffrey A. Beal, M.D. Faculty, Florida/Caribbean AIDS Education Training Center

  2. III.35 AIDP/CIDP Discuss the clinical presentation, differential diagnosis, and management of acute and chronic inflammatory demyelinating polyneuropathy in HIV+ patients

  3. III.16 Anal Pap Smears • Describe an anal Pap smear, how it is performed, and its potential use for screening for anal intraepithelial neoplasia in men and women, and discuss indications for referral to a specialist for patients with abnormal Pap smears

  4. Acute or Chronic Inflammatory Demyelinating Polyneuropathy (AIDP or CIDP) • Demyelinating Polyneuropathies are diagnosed in 1/3 of HIV+ Patients referred for peripheral nerve disease • Cause: autoimmune-induced inflammatory response and breakdown of peripheral nerve myelin

  5. Acute or Chronic Demyelinating Polyneuropathy (AIDP or CIDP) • AIDP • Rapid onset and progression • Often develops during HIV seroconversion or during early HIV infection • CIDP • More common in middle to late stages of HIV disease • Slower onset and progression over several weeks or months

  6. Acute or Chronic Demyelinating Polyneuropathy (AIDP or CIDP) • Characteristic features: • AIDP: Progressive ascending lower and upper extremity weakness, more distal than proximal • CIDP: Patchy (can be both distal and proximal) lower and upper extremity weakness • Respiratory paralysis in AIDP • Cranial neuropathy (VII, X, XII) in both

  7. Acute or Chronic Demyelinating Polyneuropathy (AIDP or CIDP) • AIDP & CIDP: • Mildly impaired sensation, mild pain • Autonomic dysfunction with cardiac arrhythmia, urinary retention, and blood pressure instability • Hyporeflexia or areflexia • Thomas, et. al.; eMedicine Journal, January 18, 2002, Vol. 3, No. 1

  8. Acute or Chronic Demyelinating Polyneuropathy (AIDP or CIDP) • CSF  increased protein with lymphocytic pleocytosis • EMG and nerve conduction velocity studies show marked slowing of nerve conduction velocities and conduction block • Nerve Biopsy macrophage-mediated segmental demyelination

  9. Acute or Chronic Demyelinating Polyneuropathy (AIDP or CIDP) • Treatment of AIDP: • Plasmapheresis or IVIG, not corticosteroids • Concomitant GCV, FOS, or, Cidofovir if CD4 < 50 • Treatment of CIDP • Prednisone • Intravenous immunoglobulin as effective as plasma exchange

  10. III.16 Anal Pap Smears • Describe an anal Pap smear, how it is performed, and its potential use for screening for anal intraepithelial neoplasia in men and women, and discuss indications for referral to a specialist for patients with abnormal Pap smears

  11. Anal Pap Smear • The incidence of anal cancer among HIV infected MSM is higher than that among HIV-negative MSM • Goedert JJ, Cote TR, Virgo P, et al. Spectrum of AIDS-associated malignant disorders. Lancet. 1998;351:1833-1839

  12. Anal Pap Smear • The incidence of anal cancer is also elevated among HIV-positive women compared to the general population. • Frisch M, et.al, Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst. 2000; 92:1500-1510

  13. Anal Intraepithelial Neoplasia • “Left untreated, anal cancer is fatal. If detected at an early stage, however, survival is excellent among both HIV + and HIV – MSM. Like cervical cancer, anal cancer is probably preventable.” • Screening for and Treatment of Anal Intraepithelial Neoplasia Joel Palefsky, MD HIV/AIDS Update 2002 MEDSCAPE 2002

  14. Anal Pap Smear • Palefsky XIV AIDS Conf reported • Prior to HIV, anal cancer incidence in MSM was 35 in 100,000 • Since 1998 the risk has more than doubled and now exceeds the risk of cervical cancer in women • Survey of >350 men in SF, anal swabs and anoscopy found early neoplasia in 52% • Risk independent of CD4 and is not decreased with HAART

  15. Anal Pap, Who to screen? • MSM • HIV infected women • HIV infected Men with history of IDU • Women with a history of high-grade CIN/cervical cancer or vulvar intraepithelial neoplasia/vulvar cancer • Men and Women with history of perianal condlyoma • Screening for and Treatment of Anal Intraepithelial Neoplasia Joel Palefsky, MD HIV/AIDS Update 2002 MEDSCAPE 2002

  16. Anal Pap Smear • Anal cytology sensitivity appears similar to cervical Pap smears, although the grade of dysplasia may not correlate as well with the histology

  17. Anal Pap Smear • Procedure: • Moistened Dacron swab inserted 1-1.5” into anal canal • Rotate swab and withdraw in a tight spiral motion. Sampling process of 15-20 seconds. • Smear on glass slide and fix immediately or use Thin Prep liquid based media

  18. Anal Pap Smear • No universally accepted guidelines • Not yet considered Standard of Care • Recommendations: • Perform at initial exam and if normal, repeat in 6 months • If initial 2 Pap smears are Normal, repeat annually. Consider more frequent when CD4 < 500 cells/mm3 • Abnormal results refer for high-resolution anoscopy and biopsy

  19. Anal Pap Smear • Cost/Benefit Analysis: • Screening q 2 years beginning during acute HIV infection hypothetical cohort HIV + MSM • Cost of $13,000 per quality-adjusted life year • Annual screening augmented this benefit at a cost of $16,000 per QALY saved • TMP-SMX for PCP prophylaxis results in cost of $13,000 per year of life saved. Goldie, et.al.; May 19, 1999; JAMA

  20. Anal Intraepithelial Neoplasia • “Treatment of AIN has not been shown to prevent anal cancer. This is a serious impediment. Unfortunately, it becomes a self-fulfilling prophecy: we will not know until we try it. Cervical cytology screening was practiced for many years before it became clear that it was contributing to the reduction in cervical cancer incidence.” • Screening for and Treatment of Anal Intraepithelial Neoplasia Joel Palefsky, MD HIV/AIDS Update 2002 MEDSCAPE 2002

  21. III.35 AIDP/CIDP Discuss the clinical presentation, differential diagnosis, and management of acute and chronic inflammatory demyelinating polyneuropathy in HIV+ patients

  22. III.16 Anal Pap Smears • Describe an anal Pap smear, how it is performed, and its potential use for screening for anal intraepithelial neoplasia in men and women, and discuss indications for referral to a specialist for patients with abnormal Pap smears

More Related